Human Oncology & Pathogenesis Program
The Asmin Tulpule Lab
The Tulpule Lab is interested in a long-standing question in cell biology: how do cells organize and compartmentalize critical cellular processes within the crowded and heterogeneous intracellular space? We focus on an emerging set of self-assembling, protein-based structures known as biomolecular condensates and their role in cancer, including a newly discovered pathogenic condensate – membraneless receptor tyrosine kinase (RTK) protein granules. Through interdisciplinary approaches combining cancer signaling, structural biology, biophysics, and high-resolution microscopy, we hope to understand how the compartmentalization of oncogenic fusion proteins can both co-opt and disrupt cellular condensates in order to drive cancer.
Menon S, Breese MR, Lin YP, Allegakoen HP, Perati S, Heslin A, Horlbeck MA, Weissman J, Sweet-Cordero EA, Trever G. Bivona#, Asmin Tulpule #. FET fusion oncoproteins disrupt physiologic DNA repair networks and induce ATR synthetic lethality in cancer. bioRxiv 2023.04.30.538578; doi: https://doi.org/10.1101/2023.04.30.538578.
Gonzalez-Martinez D, Roth L, Mumford TR, Guan J, Huang B, Tulpule A, Bivona TG, Bugaj LJ. Oncogenic protein condensates suppress growth factor perception and modulate drug tolerance. Biorxiv. doi: https://doi.org/10.1101/2022.02.02.478845
Tulpule, A*., J. Guan*, D. S. Neel*, H. R. Allegakoen, Y. P. Lin, D. Brown, Y. T. Chou, A. Heslin, N. Chatterjee, S. Perati, S. Menon, T. A. Nguyen, J. Debnath, A. D. Ramirez, X. Shi, B. Yang, S. Feng, S. Makhija, B. Huang# and T. G. Bivona# (2021). “Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.” Cell. 2021 May 13;184(10):2649-2664.
Chatterjee, N. E. Pazarentzos, M. K. Mayekar, P. Gui, D. V. Allegakoen, G. Hrustanovic, V. Olivas, L. Lin, E. Verschueren, J. R. Johnson, M. Hofree, J. J. Yan, B. W. Newton, J. V. Dollen, C. H. Earnshaw, J. Flanagan, E. Chan, S. Asthana, T. Ideker, W. Wu, J. Suzuki, B. A. Barad, Y. Kirichok, J. S. Fraser, W. A. Weiss, N. J. Krogan, A. Tulpule, A. J. Sabnis and T. G. Bivona (2019). “Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.” Cell Rep 28(9): 2317-2330.
Tulpule, A., J. M. Kelley, M. W. Lensch, J. McPherson, I. H. Park, O. Hartung, T. Nakamura, T. M. Schlaeger, A. Shimamura and G. Q. Daley (2013). “Pluripotent stem cell models of Shwachman-Diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction.” Cell Stem Cell 12(6): 727-736.
Asmin Tulpule, MD, PhD
- The Tulpule lab studies how cells compartmentalize critical cellular processes with a focus on biomolecular condensates in cancer.
- MD, Harvard Medical School
- PhD, Harvard University
- [email protected]
- Email Address
- NCI Career Development Award K08 (2023 – 2028)
- Hyundai Hope on Wheels Young Investigator Award (2023-2025)
- St. Baldrick’s Foundation Scholar Award (2018)
- UCSF Physician-Scientist Scholar Program (2017-2022)
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Asmin Tulpule discloses the following relationships and financial interests:
Professional Services and Activities
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.